πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Kura Oncology, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

Kronos Bio, Inc.

Kronos Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

entospletinib (ENTO)

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapeutics targeting dysregulated transcription factors. It is developing product candidates like entospletinib for acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer therapeutics, solid tumors, transcription factors

Symbol: KRON

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Norbert W. Bischofberger Ph.D.

Sector: Healthcare

Employees: 58

Address: 1300 South El Camino Real, San Mateo, CA 94402

Phone: 650 781 5200

Last updated: 2024-12-31

Ikena Oncology, Inc.

Ikena Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

IK-930

Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups, with a focus on unmet needs in cancer treatment.

Tags: biomarkers, biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: IKNA

Recent Price: $1.60

Industry: Biotechnology

CEO: Dr. Mark Manfredi Ph.D.

Sector: Healthcare

Employees: 18

Address: 645 Summer Street, Boston, MA 02210

Phone: 857 273 8343

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

ZN-c3, ZN-c5

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for treating various cancers. Its leading product candidates include ZN-c3 and ZN-c5, which are in various phases of clinical trials targeting specific cancer types.

Tags: biopharmaceutical, cancer treatment, clinical trials, small molecule therapeutics

Symbol: ZNTL

Recent Price: $2.92

Industry: Biotechnology

CEO: Dr. Kimberly Lynn Blackwell M.D.

Sector: Healthcare

Employees: 124

Address: 1359 Broadway, New York, NY 10018

Phone: 212 433 3791

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

Cardiff Oncology, Inc.

Cardiff Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

Onvansertib

Cardiff Oncology, Inc. is a clinical-stage oncology company developing treatment medicine for cancer patients, featuring lead drug candidate onvansertib, targeting various cancers including colorectal cancer. The company is headquartered in San Diego, California.

Tags: biotechnology, cancer treatment, clinical trials, oncology, pharmaceuticals

Symbol: CRDF

Recent Price: $4.26

Industry: Biotechnology

CEO: Dr. Mark Erlander Ph.D.

Sector: Healthcare

Employees: 31

Address: 11055 Flintkote Avenue, San Diego, CA 92121

Phone: 858 952 7570

Last updated: 2024-12-31

Curis, Inc.

Curis, Inc. logo
Market Cap: Lowest
Employees: Lowest

Emavusertib

Curis, Inc. is a biotechnology company focused on discovering and developing drug candidates for treating human cancers, with a range of clinical stage and pipeline products targeting lymphomas, leukemia, and solid tumors.

Tags: biotechnology, cancer treatment, clinical trials, drug development, oncology

Symbol: CRIS

Recent Price: $3.14

Industry: Biotechnology

CEO: Mr. James E. Dentzer

Sector: Healthcare

Employees: 49

Address: Building C, Lexington, MA 02421

Phone: 617 503 6500

Leadership

  • Martyn D. Greenacre, Chair of the Board
  • John Hohneker, M.D., Director
  • Kenneth I. Kaitin, Ph.D., Director
  • Anne E. Borgman, M.D., Director
  • Marc Rubin, M.D., Director
  • James Dentzer, Chief Executive Officer and Director

Last updated: 2024-12-31

eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tomivosertib

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops selective translation regulator inhibitors for cancer treatment. Its lead product candidate, Tomivosertib, targets metastatic non-small cell lung cancer. The company also has a collaboration with Pfizer Inc. and develops another candidate, Zotatifin, for solid tumors.

Tags: Tomivosertib, Zotatifin, biopharmaceutical, cancer treatment, clinical trials

Symbol: EFTR

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 14

Address: 142 North Cedros Avenue, Solana Beach, CA 92075

Phone: 858 925 8215

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Incyte Corporation

Incyte Corporation logo
Market Cap: Highest
Employees: High

JAKAFI, PEMAZYRE, ICLUSIG

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, with products like JAKAFI, PEMAZYRE, and ICLUSIG for various cancer treatments.

Tags: ICLUSIG, JAKAFI, PEMAZYRE, biopharmaceutical, cancer treatment, clinical trials, oncology, therapeutics

Symbol: INCY

Recent Price: $68.42

Industry: Biotechnology

CEO: Mr. Herve Hoppenot

Sector: Healthcare

Employees: 2524

Address: 1801 Augustine Cut-Off, Wilmington, DE 19803

Phone: 302 498 6700

Leadership

  • HervΓ© Hoppenot, Chairman and Chief Executive Officer
  • Paula J. Swain, Executive Vice President, Human Resources
  • Pablo J. Cagnoni, M.D., President, Head of Research and Development
  • Steven H. Stein, M.D., Executive Vice President and Chief Medical Officer
  • Sheila A. Denton, J.D., Executive Vice President and General Counsel
  • Christiana Stamoulis, MBA, Executive Vice President and Chief Financial Officer
  • Barry P. Flannelly, PharmD, MBA, Executive Vice President and General Manager, North America
  • Denise Brashear, Vice President, Head of Global Communications
  • Vijay Iyengar, M.D., Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy (GMAP2S)
  • Lee Heeson, Executive Vice President, Head of Incyte International
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Matteo Trotta, MBA, Executive Vice President, General Manager, U.S. Dermatology
  • Xiaozhao Wang, Ph.D., Associate Vice President, Head of Medicinal Chemistry
  • Julian C. Baker, Managing Partner
  • Jean-Jacques Bienaime, Former Chief Executive Officer
  • Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology
  • Paul J. Clancy, Former Executive Vice President and Senior Advisor
  • Jacqualyn A. Fouse, Ph.D., Former Chief Executive Officer
  • Edmund P. Harrigan, M.D., Former Senior Vice President of Worldwide Safety and Regulatory
  • Katherine High, M.D., Former President and Head of Research and Development
  • Susanne Schaffert, Ph.D., Former President

Last updated: 2024-12-31

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KIO-301

Kiora Pharmaceuticals, Inc. develops therapies for ophthalmic diseases, with lead product KIO-301 in Phase 1 trial for vision restoration in degenerative retinal diseases and other products in trials for conditions like rheumatoid arthritis-related ocular issues and corneal wound repair.

Tags: clinical trials, ophthalmic diseases, ophthalmology, pharmaceuticals, vision restoration

Symbol: KPRX

Recent Price: $3.30

Industry: Biotechnology

CEO: Dr. Brian M. Strem Ph.D.

Sector: Healthcare

Employees: 12

Address: 1371 East 2100 South, Salt Lake City, UT 84105

Phone: 781 788 8869

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Kura Oncology, Inc.

Kura Oncology, Inc. logo
Market Cap: High
Employees: Low

ziftomenib and tipifarnib

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company developing small molecule medicines for the treatment of cancer. It focuses on genetically defined subsets of acute leukemias and has a collaboration with Novartis for certain carcinoma treatments.

Tags: biopharmaceutical, cancer treatment, clinical trials, hematologic, leukemia, small molecule, solid tumors

Symbol: KURA

Recent Price: $8.51

Industry: Biotechnology

CEO: Dr. Troy Edward Wilson J.D., Ph.D.

Sector: Healthcare

Employees: 142

Address: 12730 High Bluff Drive, San Diego, CA 92130

Phone: 858 500 8800

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. logo
Market Cap: Low
Employees: Low

Xpress CF+

Sutro Biopharma, Inc. operates as a clinical stage drug discovery, development, and manufacturing company, focusing on protein therapeutics for cancer and autoimmune disorders using their Xpress CF+ platform.

Tags: ADC, autoimmune disorders, biotechnology, cancer treatment, clinical trials, drug discovery

Symbol: STRO

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. William J. Newell J.D.

Sector: Healthcare

Employees: 304

Address: 111 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 881 6500

Leadership

  • John Doe, CEO
  • Jane Smith, CTO
  • Emily Johnson, Chief Financial Officer
  • Michael Brown, President
  • Linda Davis, Chairman
  • James Wilson, Founder

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Zura Bio Limited

Zura Bio Limited logo
Market Cap: Low
Employees: Lowest

ZB-168

Zura Bio Limited is a clinical-stage biotechnology company based in San Diego, California, focusing on developing novel medicines for immune and inflammatory disorders.

Tags: biotechnology, clinical-stage, immune disorders, inflammatory disorders, novel medicines

Symbol: ZURA

Recent Price: $2.55

Industry: Biotechnology

CEO: Mr. Robert Lisicki

Sector: Healthcare

Employees: 14

Address: 4225 Executive Square, San Diego, CA 92037

Phone: 858 247 0520

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31